The anticancer agent 3-bromopyruvate (3-BP) is viewed as a glycolytic inhibitor that preferentially kills glycolytic cancer cells through energy depletion. However, its cytotoxic activity is dependent on cellular drug import through transmembrane monocarboxylate transporter 1 (MCT-1), which restricts its anticancer potential to MCT-1-positive tumor cells. We created and characterized an MCT-1-independent analog of 3-BP, called NEO218. NEO218 was synthesized by covalently conjugating 3-BP to perillyl alcohol (POH), a natural monoterpene.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2pfyMK9
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Pulmonary complications post hematopoietic stem cell transplant in dyskeratosis congenita: analysis of oxidative stress in lung fibrobl...
-
An examination of the etiologic overlap between the genetic and environmental influences on insomnia and common psychopathology. Depre...
-
is the premiere name in online OSHA Outreach training and safety courses. Our interactive courses include 10 hour and 30 hour OSHA Outreach,...
-
Masters Thesis Proposal Outline INTRODUCTION (1 PAGE) • What is the general topic area • Why this topic is relevant/important (how important...
-
Background. Antitumor necrosis factor (anti-TNF) therapy is a highly effective but costly treatment for inflammatory bowel disease (IBD). Me...
-
Abstract Background The introduction of aggressive chemo-radiotherapy regimens has improved overall survival in children with primitive ...
-
6 Top Reference Sites to Write a Winning Research Paper . Tina 6 Top Reference Sites to Write a Winning Research Paper. There may be guideli...
-
Abstract An analysis of dose modifications for infants in 29 Children's Oncology Group protocols across 10 cancer types revealed 11 se...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nGJfK4 via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου